Showing results (401-410 of 454) with videos related to
Sort By:
Pageof 46
Cancer Research|February 1, 1990
Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTcD M Goldenberg, H Goldenberg, R M Sharkey, et al.Cancer|December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetryT M Behr, R M Sharkey, G Sgouros, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigenM Juweid, R M Sharkey, T Behr, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emittersT M Behr, G Sgouros, M G Stabin, et al.Cancer Research|June 11, 1999
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer modelT M Behr, M Béhé, M G Stabin, et al.Lupus|August 17, 2018
Psychometric validation of the Arthritis Helplessness Index in systemic lupus erythematosusS Gholizadeh, D R Azizoddin, S D Mills, et al.Cancer Research|September 1, 1995
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivativesT M Behr, R M Sharkey, M E Juweid, et al.The Journal of Rheumatology|October 23, 1997
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquineD O Clegg, F Dietz, J Duffy, et al.Annals of the Rheumatic Diseases|September 5, 2015
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyD A Isenberg, M Petri, K Kalunian, et al.The Journal of Clinical Endocrinology and Metabolism|December 2, 2004
High frequency of bone/bone marrow involvement in advanced medullary thyroid cancerE Mirallié, J P Vuillez, S Bardet, et al.Pageof 46